Feasibility of extreme dose escalation for glioblastoma multiforme using $4\pi$ radiotherapy

Nguyen et al.
Feasibility of extreme dose escalation for glioblastoma multiforme using $4\pi$ radiotherapy

Dan Nguyen, Jean-Claude M Rwigema, Victoria Y Yu, Tania Kaprealian, Patrick Kupelian, Michael Selch, Percy Lee, Daniel A Low and Ke Sheng

Abstract

Background: Glioblastoma multiforme (GBM) frequently recurs at the same location after radiotherapy. Further dose escalation using conventional methods is limited by normal tissue tolerance. $4\pi$ non-coplanar radiotherapy has recently emerged as a new potential method to deliver highly conformal radiation dose using the C-arm linacs. We aim to study the feasibility of very substantial GBM dose escalation while maintaining normal tissue tolerance using $4\pi$.

Methods: 11 GBM patients previously treated with volumetric modulated arc therapy (VMAT/RapidArc) on the NovalisTx™ platform to a prescription dose of either 59.4 Gy or 60 Gy were included. All patients were replanned with 30 non-coplanar beams using a $4\pi$ radiotherapy platform, which inverse optimizes both beam angles and fluence maps. Four different prescriptions were used including original prescription dose and PTV ($4\pi$PTVPD), 100 Gy to the PTV and GTV ($4\pi$PTV100Gy), 100 Gy to the GTV only while maintaining prescription dose to the rest of the PTV ($4\pi$GTV100Gy), and a 5 mm margin expansion plan ($4\pi$PTVPD+5mm). OARs included in the study are the normal brain (brain – PTV), brainstem, chiasm, spinal cord, eyes, lenses, optical nerves, and cochleae.

Results: The $4\pi$ plans resulted in superior dose gradient indices, as indicated by >20% reduction in the R50, compared to the clinical plans. Among all of the $4\pi$ cases, when compared to the clinical plans, the maximum and mean doses were significantly reduced ($p < 0.05$) by a range of 47.01-98.82% and 51.87-99.47%, respectively, or unchanged ($p > 0.05$) for all of the non-brain OARs. Both the $4\pi$PTVPD and $4\pi$GTV100Gy plans reduced the mean normal brain mean doses.

Conclusions: $4\pi$ non-coplanar radiotherapy substantially increases the dose gradient outside of the PTV and better spares critical organs. Dose escalation to 100 Gy to the GTV or additional margin expansion while meeting clinical critical organ dose constraints is feasible. 100 Gy to the PTV result in higher normal brain doses but may be tolerated when delivered in proportionally increased treatment fractions. Therefore, $4\pi$ non-coplanar radiotherapy on C-arm gantry may provide an accessible tool to improve the outcome of GBM radiotherapy through extreme dose escalation.

Introduction

Glioblastoma multiforme (GBM) is a devastating disease with a dismal survival rate. Even with aggressive surgical and chemoradiation, the average survival period is 12–14 months after diagnosis [1]. Although radiotherapy has been shown to delay recurrence and prolong patient survival, GBM is remarkably resistant to treatment and has a high recurrence rate that contributes to patient mortality. The recurrence overwhelmingly occurs in or near the high-dose radiation field and original tumor site [2]. The biology behind the radiation resistance is not well understood but the pattern of recurrence suggests that there may be surviving tumor cells within or near the high dose area. This observation has motivated dose escalation studies. An increased survival period with dose escalation up to 60 Gy has been observed based on a non-randomized clinical trial [3], although this improvement was achieved without advancing the local control rates.

Dose escalation studies utilizing three-dimensional conformal radiotherapy showed that, even with dose escalation to 70 Gy and 80 Gy, the recurrences from highly conformal treatments are still predominantly local...
Further dose escalation to 90 Gy did not improve local control, instead, worsened the patient survival period possibly due to the increased treatment related toxicity [4,5]. Studies that have attempted other methods to treat GBM, such as a phase II trial utilizing weekly stereotactic radiotherapy boost [6] and a phase I trial of hypofractionated IMRT with temozolomide chemotherapy [7], have also found predominantly local recurrence and no survival benefit.

Further dose escalation using external X-ray beams alone was deemed infeasible due to normal tissue dose constraints. To increase the tumor dose, a phase II prospective trial using combined proton and photon therapy to deliver 90 Gy showed improved central tumor control, and increased median survival period to 20 months [8]. Although the total radiation dose is the same as the photon trial, the treatment was delivered in a bis in die (b.i.d. or twice a day) fashion, resulting in a substantially greater biological equivalent dose. Alternatively, a Northern California Oncology Group (NCOG) trial utilized brachytherapy to boost the tumor dose [9,10]. After being treated to a median prescription dose of 59.5 Gy via external beam radiotherapy, patients received a boost dose to the GTV from an $^{125}$I (10–40 mCi) with a dose rate of 40–60 Gy/hr to a median boost dose of 50.88 Gy within 5–6 days, totaling to approximately 110 Gy.

The results from this non-randomized clinical trial showed that the dose escalated GBM patients achieved an improved 1 and 2 year survival rate of 87% and 57% when compared to the control group receiving external beam radiation only of 40% and 12.5%, respectively. In a recurrent GBM trial using the same regimen, 10% (3) patients achieved a 5 year disease-free survival although the overall pattern of recurrence after radiotherapy and chemotherapy remained predominantly local [11]. While this treatment regimen is toxic and often results in steroid dependence and surgical removal of the necrosis induced by the aggressive treatment, it indicated the potential for substantially improving GBM patient treatment outcomes with very aggressive dose escalation to 100 Gy or greater.

Brain brachytherapy implant is associated with significant risk and the procedure itself may have contributed to the severe side effects. The complexities involved in the brachytherapy procedures and resulting patient management have prevented it from being widely and sustainably applied. At the times of the aforementioned clinical trials, external beam alone was deemed insufficiently conformal to deliver such high doses due to normal tissue dose constraints. Brain necrosis is the dominant presentation of treatment related toxicity from dose escalation studies beyond 60 Gy. Therefore, reducing the high dose spillage by increasing dose distribution compactness is critical to the success of dose escalation.

With the recent advent of highly conformal non-coplanar intensity modulated 4π therapy, markedly improved radiation dose conformity has been demonstrated [12-14]. Specifically, a significant reduction of the high dose spillage has been observed. This dosimetric improvement may afford GBM dose escalation to 100 Gy or greater using external beam only with the hope of achieving a survival benefit, without significantly increasing toxicity.

### Patients & methods

11 GBM Patients, 8 male and 3 female, were included in the study. The maximum, minimum, and median ages were 66 years, 26 years, and 49 years, respectively. Detailed patient information of 11 GBM Patients included in the study is shown in Table 1. The gross tumor volume (GTV) was delineated on a contrast enhanced magnetic resonance imaging (MRI) manually fused to the CT simulation scan. The GTV was defined as the gross disease enhancing on the T1-weighted MRI images plus any abnormal enhancement on T2-weighted and FLAIR

---

**Table 1 Basic patient information**

| Patient ID | PTV vol(cc) | 5 mm PTV vol(cc) | GTV vol(cc) | Brain vol(cc) | Non-tumor brain vol(cc) | Prescription Dose (Gy) | Number of arcs used | Site                   |
|------------|-------------|-----------------|-------------|---------------|------------------------|-----------------------|-----------------------|-----------------------|
| 1          | 262.49      | 379.9           | 66.7        | 1724.3        | 1492.0                 | 60                    | 2 non-cop            | L frontal             |
| 2          | 265.78      | 400.2           | 71.6        | 1406.6        | 1171.2                 | 60                    | 2 non-cop            | L temporal            |
| 3          | 231.97      | 368.2           | 56.7        | 1163.8        | 949.6                  | 59.4                  | 3 non-cop            | R temporal            |
| 4          | 252.33      | 363.5           | 67.9        | 1539.2        | 1321.2                 | 59.4                  | 3 non-cop            | L temporal            |
| 5          | 272.41      | 416.3           | 101.8       | 1356.1        | 1123.9                 | 59.4                  | 3 non-cop            | L frontal             |
| 6          | 426.32      | 609.5           | 132.2       | 1418.1        | 1041.6                 | 59.4                  | 3 non-cop            | R parietal            |
| 7          | 429.82      | 548.5           | 124.6       | 1241.9        | 890.7                  | 59.4                  | 2 coplanar           | L frontal             |
| 8          | 377.77      | 555.0           | 120.0       | 1473.9        | 1102.0                 | 59.4                  | 2 coplanar           | L frontal             |
| 9          | 402.40      | 567.6           | 144.5       | 1657.3        | 1306.7                 | 59.4                  | 2 coplanar           | L frontal             |
| 10         | 196.42      | 342.2           | 39.8        | 1542.5        | 1350.6                 | 59.4                  | 2 non-cop            | R Occipital           |
| 11         | 463.52      | 699.0           | 143.5       | 1398.6        | 1004.6                 | 59.4                  | 4 non-cop            | Bilateral occpt-temp  |
The clinical target volume (CTV) was then defined as the GTV + 2 cm expansion with anatomical considerations. Lastly, the planning target volume (PTV) was defined as the CTV + 0.5 cm expansion. Patients were treated to a prescription dose of either 59.4 Gy or 60 Gy to 95% of the PTV. For all patients, highly conformal volumetric modulated arc therapy (VMAT) plans were designed using Eclipse (Varian Medical Systems, Palo Alto, California) with 2 to 4 coplanar or non-coplanar arcs as necessary to achieve optimal critical structure sparing. Final dose calculation was performed using the analytical anisotropic algorithm (AAA) planning algorithm. This planning method was shown equivalent or superior to static beam IMRT, particularly with the additional partial arcs [15]. The organs-at-risk (OARs) typically involve the optical apparatus and brainstem, which are subject to maximal dose constraints and the brain, which has tolerances that depend on both the maximal and volume dose. OAR dose tolerances were defined according to RTOG protocol 0825 with the following maximum point dose constraints: chiasm <56 Gy, lens <7 Gy, brainstem <60 Gy, optic nerve <55 Gy and cochlea <45 Gy. It has been reported that in conventionally fractionated radiotherapy, a maximal dose of 72 Gy (range 60–84Gy) results in a 5% risk of symptomatic radiation necrosis at 5 years and the risk increases to 10% with 90 Gy [16]. In this study, normal brain doses greater than 60 Gy as well as the mean brain doses were constrained. In addition, it had been observed in brain SRS studies that there is a rapid rise of brain necrosis when the volume of brain receiving 12 Gy or greater (V12) is more than 5–10 cm³ [17]. This single fraction dose is biologically equivalent to 36 Gy delivered in 2 Gy daily fractions. Therefore, additional DVH points were used to pannelize normal brain receiving 30–36 Gy in the VMAT plans. Treatment was planned for a NovalisTx system equipped with a 2.5 mm leaf-width MLC.

4π non-coplanar radiotherapy was implemented following previous publications [12-14]. Briefly, 4π radiotherapy is a non-coplanar planning platform established on existing C-arm gantry linacs. The 4π optimization method starts with a candidate pool of 1162 beams evenly distributed throughout the 4π solid angle space with 6° of separation between adjacent beams. Beams causing collision between the gantry and couch or patient are excluded using a collision map based on the 3D surface image of the machine and a human subject. The remaining pool of candidate beams subdivided into 5 × 5 mm² beams, are calculated utilizing convolution/superposition of Monte Carlo calculated 6 MV poly-energetic kernels. A column generation algorithm [18] is used to iteratively select and optimize beam fluence until the desired number of beams is reached. In this case, 30 non-coplanar beams were utilized for each patient. Dose constraints similar to those of VMAT plans were applied.

The dose calculation resolution was 2.5 mm on both the clinical and 4π plans, which were then exported to a Matlab program (Computational Environment for Radiation Research CERR, Washington University) for dosimetric comparison.

Quantitative analysis was used to compare the mean and maximum OARs and PTV doses, as well as R50, a measurement of high dose spillage or dose gradient outside the PTV, which is defined as the ratio between 50% isodose volume and the PTV. V30 and V36, markers for potential brain necrosis, were assessed. To test how dose escalation affects the low dose region, V5, V10, and V20 were also evaluated. “Vx” is defined as the volume that has “x Gy” of dose or higher.

The 4π plans with the original prescription doses (4πPTVpd) were compared to the clinical plans. To test the hypothesis of minimal risk dose escalation, 3 different 4π planning schemes, including dose escalation or margin increase, were investigated.

As suggested by the literature, dose escalation from 60 Gy to 100 Gy or greater is needed to significantly improve GBM patient survival. In the first two schemes, we prescribed 100 Gy to cover 95% of the PTV and GTV, named 4πPTV100Gy and 4πGTV100Gy respectively. In the 4πGTV100Gy scheme, the remaining PTV was covered by the prescription dose. Literature also suggests that in addition to the high central recurrence rates, GBM is also likely to recur at the field margin. In the last scheme, the original PTV was further expanded by 5 mm while maintaining the original prescription doses (4πPTVpd+5mm). The expanded margins were adjusted to not extend beyond the outer skull and to avoid critical structures, unless the original PTV already encompassed part of the structure. Doses to the normal brain, which excluded the PTV contour, were evaluated. For the 4πPTVpd+5mm plan, the normal brain was still defined to exclude the original PTV.

The Wilcoxon signed-rank test was utilized to compare the 4π plans against the clinical plan. Evaluated OARs included the brain, brainstem, chiasm, spinal cord, eyes, lenses, optical nerves, and cochlea.

Results

Figure 1 shows the beam entrance patterns of a typical non-coplanar 4π plan and the corresponding VMAT plan utilizing two partial non-coplanar arcs.

All of the 4π plans exhibited a decrease in maximum and mean doses for the OARs exclusive of the brain. Table 2 lists the average percent maximum and mean OARs dose reductions for 4π compared to the clinical plans. The 4πPTVpd plans significantly reduced (p < =0.003) the maximum and mean brainstem dose by 47% and 61%.
respectively, and reduced (p ≤ 0.007) doses to all other non-brain OARs by a range of 74-98% and 90-99%, respectively. The $4\pi$PTV$_{100\text{Gy}}$ plans produced unchanged (p > 0.05) maximum and mean doses in the brainstem, and a significant decrease (p < 0.005) in the maximum and mean doses to other OARs, exclusive of the brain, in the range of 65-95% and 78-97%, respectively, except for an insignificant change (p > 0.05) in the spinal cord dose when compared to the clinical plans. The $4\pi$GTV$_{100\text{Gy}}$ study did not change the brainstem maximal doses (p > 0.05), but

Table 2 The average maximum and mean dose reduction (%) of the OARs except the normal brain

| Normal tissue comparison | $4\pi$PTV$_{100\text{Gy}}$ | $4\pi$PTV$_{100\text{Gy}}$ | $4\pi$GTV$_{100\text{Gy}}$ | $4\pi$PTV$_{P<0.005}$ |
|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                          | Average Max Dose Reduction (%) |                          |                          |                          |
|                          | % p-value % p-value % p-value % p-value |                          |                          |                          |
| Brainstem                | 47.01 0.003 7.18 0.898 27.65 0.123 30.66 0.003 |
| Chiasm                   | 84.73 <0.001 72.12 <0.001 86.74 <0.001 77.06 <0.001 |
| Spinal Cord              | 73.98 0.007 39.79 0.240 84.22 0.006 51.94 0.064 |
| Left Eye                 | 83.89 <0.001 69.03 <0.001 87.03 <0.001 66.86 <0.001 |
| Right Eye                | 89.01 <0.001 76.16 <0.001 88.11 <0.001 84.12 <0.001 |
| Left Lens                | 98.43 <0.001 94.96 <0.001 98.63 <0.001 97.53 <0.001 |
| Right Lens               | 97.74 <0.001 93.88 <0.001 98.82 <0.001 97.59 <0.001 |
| L Opt Nrv                | 87.12 <0.001 74.31 <0.001 88.45 0.002 72.44 <0.001 |
| R Opt Nrv                | 89.93 <0.001 80.42 <0.001 91.33 0.005 75.72 <0.001 |
| L Cochlea                | 82.45 <0.001 64.87 0.005 84.15 0.003 44.94 0.067 |
| R Cochlea                | 93.58 <0.001 85.19 0.001 93.10 <0.001 77.97 0.007 |
| Average Mean Dose Reduction (%) |                          |                          |                          |                          |
| Brainstem                | 60.96 0.002 38.08 0.067 57.77 <0.001 51.87 0.002 |
| Chiasm                   | 95.30 <0.001 88.88 <0.001 96.23 <0.001 92.27 <0.001 |
| Spinal Cord              | 92.43 <0.001 80.07 <0.001 98.08 <0.001 71.51 0.014 |
| Left Eye                 | 94.61 <0.001 85.66 <0.001 96.49 <0.001 89.78 <0.001 |
| Right Eye                | 95.94 <0.001 87.95 <0.001 96.69 <0.001 94.24 <0.001 |
| Left Lens                | 99.23 <0.001 97.11 <0.001 99.44 <0.001 98.56 <0.001 |
| Right Lens               | 99.10 <0.001 96.56 <0.001 99.47 <0.001 98.72 <0.001 |
| L Opt Nrv                | 95.98 <0.001 87.66 <0.001 96.96 <0.001 88.46 <0.001 |
| R Opt Nrv                | 97.48 <0.001 94.08 <0.001 98.42 <0.001 93.09 <0.001 |
| L Cochlea                | 90.34 <0.001 78.41 0.002 85.92 0.002 60.16 0.037 |
| R Cochlea                | 96.83 <0.001 92.81 0.003 97.79 <0.001 90.83 0.002 |
reduced its mean doses by 57.77% (p < 0.001). The remaining OARs, exclusive of the brain, showed a significant decrease (p < 0.006) in the maximum and mean doses by a range of 84-99% and 86-99%, respectively. The 4πPTV\textsubscript{PD+5mm} plan significantly reduced the (p = 0.003) maximum and mean doses for the brainstem by 31% and 52%, respectively, and reduced (p < 0.04) the maximum and mean doses to other OAR, exclusive of the brain, by a range of 67-98% and 60-99%, respectively, except for the unchanged (p > 0.05) maximum doses in the spinal cord and left cochlea, when compared to the clinical plans.

Figure 2 compares the normal brain maximum dose, mean dose, V30, and V36 between the clinical plan and the 4π plans. The 4πPTV\textsubscript{PD} plans significantly reduced (p < 0.001) the mean brain dose from 21.94 Gy to 16.56 Gy and slightly increased the maximum normal brain doses (p < 0.001) from 63.24 to 64.88 Gy. The maximum normal brain doses increased (p < 0.001) in the 4πPTV\textsubscript{100Gy} and 4πGTV\textsubscript{100Gy} plans to 108.71 Gy and 98.51 Gy respectively. The 4πPTV\textsubscript{100Gy} plans also significantly increased (p < 0.001) the mean brain dose to 27.60 Gy (26%), while the 4πGTV\textsubscript{100Gy} significantly decreased (p < 0.001) the mean brain dose to 17.61 Gy (20%). For the 4πPTV\textsubscript{PD+5mm} plans, the maximum brain dose slightly increased (p < 0.001) from 63.24 Gy to 64.94 Gy, and the brain mean dose was statistically unchanged (p > 0.05).

Brain dose comparison for individual patients is shown in Figure 2. V36 and V30, surrogates for potential brain necrosis, were significantly decreased (p < 0.001), for the 4πPTV\textsubscript{PD} and the 4πGTV\textsubscript{100Gy} plans, statistically unchanged for the 4πPTV\textsubscript{PD+5mm} plan, and significantly increased (p < 0.001) for the 4πPTV\textsubscript{100Gy} plan. In the 4πPTV\textsubscript{PD} and 4πGTV\textsubscript{100Gy} plans, the brain V36 significantly decreased (p < 0.001) by 94.77 cm\textsuperscript{3}, 90.92 cm\textsuperscript{3}, respectively. Similarly, the brain V30 decreased by 144.92 cm\textsuperscript{3}, 127.63 cm\textsuperscript{3} for the same plans. The brain V36 and V30 of the 4πPTV\textsubscript{100Gy} plan significantly increased (p < 0.001) by 108.62 cm\textsuperscript{3} and 91.81 cm\textsuperscript{3}, respectively. V5, V10, and V20 were also significantly decreased (p < 0.01) in the the 4πPTV\textsubscript{PD} and 4πGTV\textsubscript{100Gy} plans, and statistically unchanged (p > 0.05) in the 4πPTV\textsubscript{PD+5mm} and 4πPTV\textsubscript{100Gy} plan. A comparison of the average volumes plotted against the various “Vx” are shown in Figure 3.

Figure 4 shows a dose colorwash superimposed on the planning CT for a typical case. The dose fall-off outside the PTV is steeper in the 4π cases. R50 was significantly lowered from 2.52 in the clinical plans to 1.97 (4πPTV\textsubscript{PD}), 2.00 (4πPTV\textsubscript{100Gy}), 2.10 (4πGTV\textsubscript{100Gy}), and 1.75 (4πPTV\textsubscript{PD+5mm}) respectively. The DVHs shown in Figure 5 compare the PTV and the brain doses. With the exception of the 4πPTV\textsubscript{100Gy} plans, the 4π plans reduced dose to the brain and brainstem while maintaining superior doses to the tumor. 4π plans resulted in essentially equivalent or slightly superior PTV coverage compared to the clinical plans.

**Discussion**

GBM tumors are nested within the normal brain tissue and are often proximal to other serial critical organs. Currently established dose of approximately 60 Gy to the GBM tumor has shown survival benefit compared to lower doses but milder dose escalation from this dose.
has not improved patient survival or local control. Dose escalation studies to over 100 Gy or therapy using boron neutron capture therapy [19] with high radiobiological equivalent dose show that very aggressive dose escalation could provide meaningful improvement in tumor response. However, attempting dose escalation without drastically improving the dose compactness will result in a greater severe toxicity risk long before reaching a tumor doses that can significantly delay GBM recurrence, let alone the dose needed for permanent local tumor control. Previous dose escalation studies utilizing 3D conformal radiation therapy have shown worse patient survival [4,5] largely due to the lack of dose conformity around the target. Compared to 3D conformal radiation therapy used in the aforementioned clinical trials, intensity modulated radiation therapy (IMRT) better conforms radiation doses to the target. However, intensity modulation does not fundamentally change the “compactness” of dose distribution [20], which has been commonly defined using the ratio of the 50% isodose volume to the PTV volume. Previous dose escalation studies to beyond 100 Gy BED had to utilize proton therapy or brachytherapy, severely limiting their applicability [8-10]. Brachytherapy particularly increases the bleeding and infection risk, making it a less appealing option for many clinics.

It has been previously shown that $4\pi$ radiotherapy will provide improved dose compactness compared to coplanar arc and manually selected non-coplanar IMRT approaches [12]. Selecting and optimizing beams in the vast non-coplanar solution space is an enormously complex problem that has become manageable using innovative optimization algorithms such as the column generation approach. Using our $4\pi$ research-planning platform, we showed that GTV dose escalation to 100 Gy is achievable while maintaining lower mean and maximum OAR doses. Use of this technique may result in delayed or reduced central recurrences. To effectively reduce marginal recurrences, dose escalation to the entire PTV or

![Figure 3 Comparison of volumes between the clinical and 4\pi plans.](image)

![Figure 4 Dose wash of the clinical case and the various 4\pi plans for a single patient.](image)
more is needed. We showed that by using 4π, an additional 5 mm can be added without increasing normal tissue doses. The 4πPTV_{100Gy} plans unavoidably increased the brain maximum and mean doses and V30 and V36. It remains to be seen whether these doses could be safely delivered, but if a consistent fractionation is employed, the greater doses will be delivered using more fractions. For example, delivering the 100 Gy in 50 fractions instead of the 30–33 fractions required for the original plan, the biological equivalent dose to normal brain tissue would be decreased from between 211.11 and 201.01 Gy to 166.67 Gy.

Like all dosimetry comparison studies, there is often question whether the best possible plan has been achieved in either planning platform. While subjective biases cannot be completely ruled out, the large differences in normal organ doses exceed typical variation in plan quality from the same planning platform. Furthermore, R50 as a measurement of dose compactness has been a highly reproducible parameter that is not substantially affected by the selection of penalties and constraints in optimization. Therefore, the observed significant difference in R50 is unlikely due to operators.

Therefore, with the advent of 4π radiotherapy, it is now feasible to employ markedly improved dose conformity and compactness for meaningful GBM dose escalation using external beam X-rays alone. 4π radiotherapy using C-arm gantries is less invasive than brachytherapy and more accessible than proton beams. There are practical hurdles to deliver these plans, namely collision avoidance and delivery efficiency. While collision angles can be excluded based on the patient specific surface measurements, the delivery time will include the greater time required to move the couch and gantry between the numerous beams. Based on our experience delivering 4π test plans on a TrueBeam machine (Varian, Palo Alto) using automated sequencing, the total time for the machine to travel between 30 non-coplanar beams was less than 200 seconds and total treatment time from the first to the last beam less than 15 minutes. The couch rotation in a typical 4π treatment involves many small steps totaling less than 180°. Such magnitudes of couch kicks are routinely used in linac based brain stereotactic radiosurgery and appear to be well tolerated. Overcoming these practical hurdles and integrating 4π into a clinical delivery flow will allow for equivalent or better patient survival than the previous dose escalation studies.

**Conclusion**

The significantly improved dose coverage and high dose conformity of 4π radiotherapy made it possible to escalate the GBM prescription doses from 60 Gy to 100 Gy or to increase the PTV margins while meeting clinical critical organ dose constraints. For GBM, this 4π non-coplanar radiotherapy modality may subsequently improve the GBM treatment outcome.

**Consent**

An institutional review board (IRB) protocol has been approved for retrospectively accessing and the publication of anonymized patient data. Individual patient consent was not necessary.

**Competing interests**

KS and PK receive research grants from Varian Medical Systems.

**Authors’ contributions**

KS designed and coordinated the study. TK, PK, MS and PL provided patient data and reviewed the dosimetry. DN and JR performed the 4π dosimetry. DN and VY performed data analysis and statistics. DN, KS and DL drafted the manuscript. All authors read and approved the final manuscript.

**Acknowledgement**

This study was supported in part by Varian Medical Systems.

**Received:** 12 August 2014 **Accepted:** 16 October 2014

**Published online:** 07 November 2014

**References**

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Veicht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T,
Weller M, Lacombe D, Caimcross JS, Mitmanoff RO: Effects of radiotherapy with concomitant and adjuvant temozolomide versus adjuvant radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 2009, 10:e59–66.

2. Wallner KE, Galicich JH, Krol G, Arbit E, Makin MG: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. *Int J Radiat Oncol Biol Phys* 1989, 16:1405–1409.

3. Walker MD, Strike TA, Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. *Int J Radiat Oncol Biol Phys* 1979, 5:1725–1731.

4. Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, Gebarski SS, Sandler HM: Survival and Failure Patterns of High-Grade Gliomas After Three-Dimensional Conformal Radiotherapy. *J Clin Oncol* 2002, 20:1635–1642.

5. Lee SW, Fraass BA, Marsh LH, Herbolt K, Gebarski SS, Martel MK, Radany EH, Lichter AS, Sandler HM: Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. *Int J Radiat Oncol Biol Phys* 1999, 43:79–88.

6. Cardinale R, Won M, Chouraci A, Gilin M, Chalkevanti A, Schultz C, Souharni L, Chen A, Pham H, Mehta A: A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. *Int J Radiat Oncol Biol Phys* 2006, 65:1422–1428.

7. Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rutherford KE, Kavanagh BD: Phase I Trial of Hypofractionated Intensity-Modulated Radiotherapy With Temozolomide Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme. *Int J Radiat Oncol Biol Phys* 2011, 81:1066–1074.

8. Fitzek WM: Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: Results of a phase IIb prospective trial. *J Neurosurg* 1999, 91:251–260.

9. Gustin PH, Prados MD, Phillips TL, Wara WM, Larson DA, Leibel SA, Sneed PK, Levin VA, Weaver KA, Silver P, Lamborn K, Lamb S, Ham B: External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2. *Int J Radiat Oncol Biol Phys* 1991, 21:601–606.

10. Prados MD, Gustin PH, Phillips TL, Wara WM, Sneed PK, Larson DA, Lamb SA, Ham B, Malek MK, Wilson GB: Intertstitial brachytherapy for newly diagnosed patients with malignant gliomas: The UCSF experience. *Int J Radiat Oncol Biol Phys* 1992, 24:593–597.

11. Sneed PK, Gustin PH, Larson DA, Malek MK, Phillips TL, Prados MD, Sarafian CO, Weaver KA, Wara WM: . Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. *Int J Radiat Oncol Biol Phys* 1994, 29:719–727.

12. Dong P, Lee P, Ruan D, Long T, Romeijn E, Low DA, Kupelian P, Abraham J, Yang Y, Sheng K: 4D Noncoplanar Stereotactic Body Radiation Therapy for Centrally Located or Larger Lung Tumors. *Int J Radiat Oncol Biol Phys* 2013, 86:407–413.

13. Dong P, Lee P, Ruan D, Long T, Romeijn E, Yang Y, Low D, Kupelian P, Sheng K: 4D Non-Coplanar Liver SBRT: A Novel Delivery Technique. *Int J Radiat Oncol Biol Phys* 2013, 85:1360–1366.

14. Dong P, Nguyen D, Ruan D, King C, Long T, Romeijn E, Low D, Kupelian P, Steinberg ML, Yang Y, Sheng K: Feasibility of prostate robotic radiation on conventional C-arm linac. *Pract Radiat Oncol* 2014, 4:254–260.

15. Davidson MT, Masucci GL, Follwell M, Blake SJ, Xu W, Moseley DJ, Sanghera P, Wong CS, Perry J, Tsao M, Saghafi A: Single arc volumetric modulated arc therapy for complex brain gliomas: is there an advantage as compared to intensity modulated radiotherapy or by adding a partial arc? *Technol Cancer Res Treat* 2012, 11:211–220.

16. Lawrence YR, Li KA, el Naqa I, Hahn CA, Marks LB, Merchant TE, Dicker AP: Radiation Dose–Volume Effects in the Brain. *Int J Radiat Oncol Biol Phys* 2010, 76:520–527.

17. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Conrste LS, Eisbruch A, Bentzen SM, Nam J, Deasy JO: Use of Normal Tissue Complication Probability Models in the Clinic. *Int J Radiat Oncol Biol Phys* 2010, 76:510–519.

18. Romeijn H, Ahuja R, Dempsey J, Kumar A: A Column Generation Approach to Radiation Therapy Treatment Planning Using Aperture Modulation. *SIAM J Optim* 2005, 15:838–862.

19. Kageji T, Mizobuchi Y, Nagahiro S, Nakagawa Y, Kumada H: Long-survivors of glioblastoma treated with boron neutron capture therapy (BNCT). *Appl Radiat Isot* 2011, 69:1800–1802.

20. Reese AS, Das SK, Curie C, Marks LB: Integral dose conservation in radiotherapy. *Med Phys* 2009, 36:734–740.

Cite this article as: Nguyen et al.: Feasibility of extreme dose escalation for glioblastoma multiforme using 4n radiotherapy. *Radiation Oncology* 2014 9:235.